European Journal of Cancer
Volume 41, Issue 11 , Pages 1551-1559 , July 2005

Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer

  • Ian Chau

      Affiliations

    • Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    • ,
  • Andrew R. Norman

      Affiliations

    • Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    • ,
  • David Cunningham

      Affiliations

    • Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44 208 661 3156; fax: +44 208 643 9414.
    • ,
  • Tim Iveson

      Affiliations

    • Southampton General Hospital and Salisbury District Hospital, United Kingdom
    • ,
  • Mark Hill

      Affiliations

    • Kent Oncology Centre, Maidstone, United Kingdom
    • ,
  • Tamas Hickish

      Affiliations

    • Royal Bournemouth and Poole Hospitals, Dorset, United Kingdom
    • ,
  • Fiona Lofts

      Affiliations

    • St. George’s Hospital, London, United Kingdom
    • ,
  • Duncan Jodrell

      Affiliations

    • Western General Hospital, Edinburgh, United Kingdom
    • ,
  • Andrew Webb

      Affiliations

    • Brighton and Sussex University Hospital, Brighton, United Kingdom
    • ,
  • Diana Tait

      Affiliations

    • Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    • ,
  • Paul J. Ross

      Affiliations

    • Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    • ,
  • Pat Shellito

      Affiliations

    • Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    • ,
  • Jacqueline R. Oates

      Affiliations

    • Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom

Received 10 November 2004 ,Revised 18 January 2005 ,Accepted 26 January 2005.

References 

  1. Ramsey SD, Berry K, Moinpour C, et al. Quality of life in long term survivors of colorectal cancer. Am J Gastroenterol. 2002;97:1228–1234
  2. Ramsey SD, Andersen MR, Etzioni R, et al. Quality of life in survivors of colorectal carcinoma. Cancer. 2000;88:1294–1303
  3. Trentham-Dietz A, Remington PL, Moinpour CM, et al. Health-related quality of life in female long-term colorectal cancer survivors. Oncologist. 2003;8:342–349
  4. Mosconi P, Apolone G, Barni S, et al. Quality of life in breast and colon cancer long-term survivors: an assessment with the EORTC QLQ-C30 and SF-36 questionnaires. Tumori. 2002;88:110–116
  5. Rauch P, Miny J, Conroy T, et al. Quality of life among disease-free survivors of rectal cancer. J Clin Oncol. 2004;22:354–360
  6. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med. 1990;9:1259–1276
  7. Glasziou PP, Cole BF, Gelber RD, et al. Quality adjusted survival analysis with repeated quality of life measures. Stat Med. 1998;17:1215–1229
  8. Chau I, Norman AR, Cunningham D, et al. A randomised comparison between six months of bolus fluorouracil/leucovorin and twelve weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol. 2005;16:549–557
  9. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376
  10. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  11. Billingham LJ, Abrams KR. Simultaneous analysis of quality of life and survival data. Stat Methods Med Res. 2002;11:25–48
  12. Efron B, Tibshirani RJ. An introduction to the bootstrap. 1993;
  13. Bernhard J, Hurny C, Maibach R, et al. Quality of life as subjective experience: reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapy. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 1999;10:775–782
  14. Guren MG, Dueland S, Skovlund E, et al. Quality of life during radiotherapy for rectal cancer. Eur J Cancer. 2003;39:587–594
  15. Engel J, Kerr J, Schlesinger-Raab A, et al. Quality of life in rectal cancer patients: a four-year prospective study. Ann Surg. 2003;238:203–213
  16. Sprangers MA, te VA, Aaronson NK. The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Eur J Cancer. 1999;35:238–247
  17. Kilbridge KL, Cole BF, Kirkwood JM, et al. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol. 2002;20:1311–1318
  18. Cole BF, Gelber RD, Gelber S, et al. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet. 2001;358:277–286
  19. Mounier N, Haioun C, Cole BF, et al. Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d’Etude les Lymphomes de l’Adulte (GELA). Blood. 2000;95:3687–3692
  20. Cole BF, Solal-Celigny P, Gelber RD, et al. Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. J Clin Oncol. 1998;16:2339–2344
  21. Cole BF, Gelber RD, Kirkwood JM, et al. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1996;14:2666–2673
  22. Gelber RD, Goldhirsch A, Cole BF, et al. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst. 1996;88:1039–1045
  23. Gelber RD, Cole BF, Goldhirsch A, et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet. 1996;347:1066–1071
  24. Zee B, Cole B, Li T, et al. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. J Clin Oncol. 1998;16:2834–2839
  25. Scheithauer W, McKendrick J, Begbie S, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol. 2003;14:1735–1743
  26. Cassidy J, Scheithauer W, McKendrick J, et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): positive efficacy results of a phase III trial. J Clin Oncol (Meeting Abstracts). 2004;22:3509

PII: S0959-8049(05)00282-0

doi: 10.1016/j.ejca.2005.01.027

European Journal of Cancer
Volume 41, Issue 11 , Pages 1551-1559 , July 2005

Article Tools

* Image Usage & Resolution